





/data, stamp of the Bidder/ Offer form In response to the Request for Quotation No. 2/04/2023 https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl No. (2023-31107-154074) of 10 April 2023, submitted by NEURO_OPIOMEL sp. z o.o. in connection with the mplementation of the project entitled "Opioid-melanocortin peptidomimetics for the treatment of neuropathic pain" co-financed by the European Regional Development Fund under Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. If we the undersigned									
Offer form n response to the Request for Quotation No. 2/04/2023 https://bazakonkurencyinosci.funduszeeuropejskie.gov.pl No. (2023-31107-154074) of 10 April 2023, submitted by NEURO_OPIOMEL sp. z o.o. in connection with the mplementation of the project entitled "Opioid-melanocortin peptidomimetics for the treatment of neuropathic pain" co-financed by the European Regional Development Fundunder Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned									/place, date/
Offer form n response to the Request for Quotation No. 2/04/2023 https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl No. (2023-31107-154074) of 10 April 2023, submitted by NEURO_OPIOMEL sp. z o.o. in connection with the mplementation of the project entitled "Opioid-melanocortin peptidomimetics for the creatment of neuropathic pain" co-financed by the European Regional Development Fundunder Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned									
Offer form n response to the Request for Quotation No. 2/04/2023 https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl No. (2023-31107-154074) of 10 April 2023, submitted by NEURO_OPIOMEL sp. z o.o. in connection with the mplementation of the project entitled "Opioid-melanocortin peptidomimetics for the creatment of neuropathic pain" co-financed by the European Regional Development Fundunder Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned									
n response to the Request for Quotation No. 2/04/2023 https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl No. (2023-31107-154074) of 10 April 2023, submitted by NEURO_OPIOMEL sp. z o.o. in connection with the mplementation of the project entitled "Opioid-melanocortin peptidomimetics for the treatment of neuropathic pain" co-financed by the European Regional Development Fundunder Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned									
https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl No. (2023-31107-154074) of 10 April 2023, submitted by NEURO_OPIOMEL sp. z o.o. in connection with the mplementation of the project entitled "Opioid-melanocortin peptidomimetics for the creatment of neuropathic pain" co-financed by the European Regional Development Fundunder Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned					Offer	form			
of 10 April 2023, submitted by NEURO_OPIOMEL sp. z o.o. in connection with the mplementation of the project entitled "Opioid-melanocortin peptidomimetics for the creatment of neuropathic pain" co-financed by the European Regional Development Fund under Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned	In re	esponse	to	the	Request	for	Quotation	No.	2/04/2023
In the undersigned	(<u>https://</u>	<u>bazakonku</u>	rencyjn	osci.fun	<u>duszeeurope</u>	jskie.gov	<u>.pl</u> No. (2	023-311	07-154074)
reatment of neuropathic pain" co-financed by the European Regional Development Fund under Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned	of 10 A	April 2023,	subm	itted by	/ NEURO_OF	PIOMEL	sp. z o.o. in	connectio	on with the
Under Sub-measure 1.1.1 of the Smart Growth Operational Programme 2014 - 2020, the Fast Track for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned	•		•	-	•		• •		
Irack for Mazovia competition No. 3/1.1.1/2020, Project No. POIR.01.01.01-00-0576/20. I/we the undersigned (First names and surnames of persons authorised to represent the Bidder)			•	•		•			•
I/we the undersigned(First names and surnames of persons authorised to represent the Bidder)						-	_		
surnames of persons authorised to represent the Bidder)	Track for	r Mazovia c	ompeti	tion No.	3/1.1.1/202	0, Projec	t No. POIR.01.0	1.01-00-0	5/6/20.
surnames of persons authorised to represent the Bidder)									
surnames of persons authorised to represent the Bidder)									
	I/we the	undersigned	d					(Fir	st names and
			surnar	nes of ne	rsons authoris	sed to ren	resent the Bidde	r)	
acting for and on behalf of:			Jannan		750715 444710775	eu to rep	reserve tire Brade.	,	
	acting for	and on beh	alf of:						
	_								
		•••••							
(Full name and address of the Bidder)				(Full n	name and add	ress of the	e Ridder)		

I / we make the following offer for successive deliveries (the quantities given represent the target amount of the reagent / material to be achieved in the consecutive deliveries):







		Net price*	Gross price*				
Lp.	Our offer includes:						
		PLN	PLN				
In v	vitro study of the nephrotoxicity, hepatoxi	city and neu	rotoxicity of				
pep	tidomimetic						
1a	Study of the nephrotoxicity of peptidomimetic in GLP						
1b	Study of the nephrotoxicity of peptidomimetic in non-GLP						
2a	Study of the hepatoxicity of peptidomimetic in GLP.						
2 a	Study of the hepatoxicity of peptidomimetic in-non GLP.						
3 a	Study of the neurotoxicity of peptidomimetic in GLP						
3b	Study of the neurotoxicity of peptidomimetic in non-GLP						
	Total price:						
* rem	fremuneration in the amount of the PLN equivalent of						

* remun	eration	in the	amount of t	he Pi	LN equ	uivalent	of	E	UR, whi	ich as
) ne 	t and PLN
` '										
gross aco Poland (v	•		•	chan	ge rat	e of for	eign	currencies - table A of the Nati	onal Ba	nk of

We commit ourselves / we do not commit ourselves *) to implement the subject matter of the contract with respect to the principle of sustainable development and with attention to limit the impact on the environment and climate – in particular by reducing energy consumption of the equipment used, reducing water consumption, amount of waste, as well as by striving to use recycled materials, etc.

Validity of the offer: The offer is valid until







I/We declare that I/we have got acquainted with information included in the Request for Quotation and I/we do not make any objections.

I/we* attach to this offer:

- 1. Declaration of meeting the conditions for participation in the procedure YES/NO *);
- A completed Technical Information Sheet confirming that the surface offered meets the technical specifications required by the Ordering Party - YES/NO *);
- 3. Declaration of no capital and personal ties YES/NO *);

Signature of person/s authorised to represent the Bidder

*) delete as appropriate







	/place, date/
/data, stamp of the Bidder/	
Declaration of meeting the con 154074)	ditions for participation in the procedure (No. 2023-31107-
	omitted in response to the Request for Quotation No. 2/04/2023, norised to conduct activities related to the subject matter of the
	Signature of person/s authorised to represent the Bidder
	omitted in response to the Request for Quotation No. 2/04/2023, cal capacity necessary for the implementation of the subject
	Signature of person/s authorised to represent the Bidder
	abmitted in response to the Request for Quotation No. 2/04/2023, omic and financial situation allowing for the implementation of the
	Signature of person/s authorised to represent the Bidder







we decl	ubmitted in response to the inquiry No. 2/04/2023, I declare a entity related directly or indirectly personally or capitally with tions have been imposed.
	Signature of person/s authorised

to represent the Bidder







	/place, date/
/data, stamp of the Bidder/	

Completed Technical Information Sheets confirming that the service meets the technical specifications required by the Ordering Party

In connection with the Offer submitted in response to the Request for Quotation No. 2/04/2023 (2023-31107-154074), I/we declare that the offered products meets the requirements of the technical specification (*Provider fills the table for offered position of materials/chemicals*):

In vitro study of the nephrotoxicity, hepatoxicity and neurotoxicity of peptidomimetic

1. Study of the nephrotoxicity of peptidomimetic.

L.p.	Parameter or function name	Required	response	Ans	wer
				Contr	actors
1.	Study of the nephrotoxicity of one	YES	Please		
	peptidomimetic on human renal proximal		indicate the		
	tubule epithelial cells in GLP.		unit price		
2.	Study of the nephrotoxicity of one	YES	Please		
	peptidomimetics on human renal proximal		indicate the		
	tubule epithelial cells in non-GLP.		unit price		
3.	Please send a description of the tests that	Υ	ES		
	will be used to determine the				







	nephrotoxicity.		
	8 concentrations of peptidomimetic will be tested, in 3 technical replicates.		
	At least two independent experiments should be performed.		
4.	Results should be expressed in report format in English.	YES	
5.	Please specify the amount of substance needed for the study in [mg].	Please specify	
6.	Turnaround time per order.	Please specify the calendar number days	
7.	Approximate start time of the study after receipt of the peptidomimetic.	Please specify the calendar number days	
8.	The laboratory has qualified personnel and experience in the implementation of similar orders.	YES	







2. Study of the hepatoxicity of peptidomimetic.

L.p.	Parameter or function name	Require	ed response	Ans	wer
				Contr	actors
1.	Study of the hepatoxicity of one peptidomimetic on human primary hepatocytes in GLP.	YES	Please indicate the unit price		
2.	Study of the hepatoxicity of one peptidomimetics on human primary hepatocytes in non-GLP.	YES	Please indicate the unit price		
3.	Please send a description of the tests that will be used to determine the hepatoxicity. 8 concentrations of peptidomimetic will be tested, in 3 technical replicates. At least two independent experiments should be performed.		YES		
4.	Results should be expressed in report format in English.	YES			
5.	Please specify the amount of substance needed for the study in [mg].	Pleas	e specify		
6.	Turnaround time per order.	Please specify the calendar number days			
7.	Approximate start time of the study after receipt of the peptidomimetic.		ify the calendar ber days		







8.	The laboratory has qualified personnel and	YES	
	experience in the implementation of similar		
	orders.		

3. Study of the neurotoxicity of peptidomimetic.

L.p.	Parameter or function name	Required response		Ans	wer
				Contr	actors
1.	Study of the neurotoxicity of one peptidomimetic on human primary neural cells in GLP.	YES	Please indicate the unit price		
2.	Study of the neurotoxicity of one peptidomimetic on human primary neural cells in non-GLP.	YES	Please indicate the unit price		
3.	Please send a description of the tests that will be used to determine the neurotoxicity. 8 concentrations of peptidomimetic will be tested, in 3 technical replicates. At least two independent experiments should be performed.		YES		
4.	Results should be expressed in report format in English.		YES		
5.	Please specify the amount of substance needed for the study in [mg].	Pleas	e specify		







6.	Turnaround time per order.	Please specify	
7.	Approximate start time of the study after receipt of the peptidomimetic.	Please specify	
8.	The laboratory has qualified personnel and experience in the implementation of similar orders.	YES	

, on	
	(signature of the authorised
	Contractor's representative)







	/place, date/
/data, stamp of the Bidder/	

Declaration of no capital and personal ties

I/we declare that there are no prerequisites regarding personal or capital ties with the Contracting Party (NEURO-OPIOMEL sp. z o.o.),

i.e. capital or personal ties shall be understood as mutual ties between the Ordering Party or persons authorised to incur liabilities on behalf of the Ordering Party or persons carrying out activities related to the execution of the selection procedure of the Contractor on behalf of the Ordering Party and the Contractor (Bidder), consisting in particular of:

- a) participation in a partnership as a partner of a professional partnership or registered partnership;
- b) possession of 10 % or more of stocks and shares,
- c) being a member of a supervisory or management body, proxy, attorney,
- d) maintaining a legal or factual relation that may arouse justified doubts as to the impartiality in selecting the Contractor, including, without limitation, marriage, straight-line relationship by blood or affinity, collateral-line relationship by blood or affinity up to the second degree, or adoption, custody or guardianship.

Signature of person/s authorised to represent the Bidder